287 related articles for article (PubMed ID: 10759005)
1. Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays.
Beeck H; Nagel D; Pindur G; Scharrer I; Preiss A; Seiler D; Hellstern P
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):127-35. PubMed ID: 10759005
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel, rapid assay for detection of heparin-binding defect antithrombin deficiencies: the heparin-antithrombin binding (HAB) ratio.
Moore GW; de Jager N; Cutler JA
Thromb Res; 2015 Jan; 135(1):161-6. PubMed ID: 25466846
[TBL] [Abstract][Full Text] [Related]
3. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
Rezaie AR
Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
[TBL] [Abstract][Full Text] [Related]
4. Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era.
Rühl H; Reda S; Müller J; Oldenburg J; Pötzsch B
Thromb Haemost; 2018 Feb; 118(2):381-387. PubMed ID: 29378360
[TBL] [Abstract][Full Text] [Related]
5. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
Demers C; Henderson P; Blajchman MA; Wells MJ; Mitchell L; Johnston M; Ofosu FA; Fernandez-Rachubinski F; Andrew M; Hirsh J
Thromb Haemost; 1993 Mar; 69(3):231-5. PubMed ID: 8470046
[TBL] [Abstract][Full Text] [Related]
6. Progressive chromogenic anti-factor Xa assay and its use in the classification of antithrombin deficiencies.
Kovács B; Bereczky Z; Selmeczi A; Gindele R; Oláh Z; Kerényi A; Boda Z; Muszbek L
Clin Chem Lab Med; 2014 Dec; 52(12):1797-806. PubMed ID: 24968404
[TBL] [Abstract][Full Text] [Related]
7. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
Elgue G; Blombäck M; Olsson P; Riesenfeld J
Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
[TBL] [Abstract][Full Text] [Related]
8. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
Peyrou V; Béguin S; Boneu B; Hemker HC
Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
[TBL] [Abstract][Full Text] [Related]
9. Conventional chromogenic heparin assays are influenced by patient's endogenous plasma Antithrombin levels.
Mitchell LG; Vegh P
Klin Padiatr; 2010 May; 222(3):164-7. PubMed ID: 20514621
[TBL] [Abstract][Full Text] [Related]
10. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays.
Harris LF; O'Brien A; Castro-López V; O'Donnell JS; Killard AJ
Thromb Res; 2011 Dec; 128(6):e166-70. PubMed ID: 21872908
[TBL] [Abstract][Full Text] [Related]
12. Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system.
Furugohri T; Sugiyama N; Morishima Y; Shibano T
Thromb Haemost; 2011 Dec; 106(6):1076-83. PubMed ID: 22012070
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma.
Brooks MB
Vet Clin Pathol; 2004; 33(4):208-14. PubMed ID: 15570557
[TBL] [Abstract][Full Text] [Related]
14. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
Bohner J; von Pape KW; Blaurock M
Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
[TBL] [Abstract][Full Text] [Related]
15. The superiority of anti-FXa assay over anti-FIIa assay in detecting heparin-binding site antithrombin deficiency.
Kovács B; Bereczky Z; Oláh Z; Gindele R; Kerényi A; Selmeczi A; Boda Z; Muszbek L
Am J Clin Pathol; 2013 Nov; 140(5):675-9. PubMed ID: 24124146
[TBL] [Abstract][Full Text] [Related]
16. Great discrepancy in antithrombin activity measured using five commercially available functional assays.
Javela K; Engelbarth S; Hiltunen L; Mustonen P; Puurunen M
Thromb Res; 2013 Jul; 132(1):132-7. PubMed ID: 23768451
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
[TBL] [Abstract][Full Text] [Related]
18. The Homozygous Type II Antithrombin Deficient Pregnant Woman Monitored by Thrombin Generation Assay.
Malikova I; Husakova M; Bilkova J; Brzezkova R; Hrachovinova I; Kvasnicka T
Clin Lab; 2023 Oct; 69(10):. PubMed ID: 37844053
[TBL] [Abstract][Full Text] [Related]
19. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.
Mani H; Rohde G; Stratmann G; Hesse C; Herth N; Schwers S; Perzborn E; Lindhoff-Last E
Thromb Haemost; 2012 Jul; 108(1):191-8. PubMed ID: 22534775
[TBL] [Abstract][Full Text] [Related]
20. Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.
Bray B; Lane DA; Freyssinet JM; Pejler G; Lindahl U
Biochem J; 1989 Aug; 262(1):225-32. PubMed ID: 2818566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
